AQR Capital Management’s Ginkgo Bioworks DNA Stock Holding History

AQR Capital Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.16M	Buy	621,625 +326,837	+111%	+$2.73M	﹤0.01%	1871
2026 Q1	$1.81M	Buy	294,788 +124,233	+73%	+$1.03M	﹤0.01%	2421
2025 Q4	$1.42M	Buy	170,555 +19,860	+13%	+$214K	﹤0.01%	2350
2025 Q3	$2.2M	Sell	150,695 -13,095	-8%	-$157K	﹤0.01%	1923
2025 Q2	$1.84M	Buy	163,790 +4,851	+3%	+$37.6K	﹤0.01%	1825
2025 Q1	$906K	Buy	158,939 +121,326	+323%	+$1.24M	﹤0.01%	2088
2024 Q4	$369K	Sell	37,613 -2,818	-7%	-$24.2K	﹤0.01%	2400
2024 Q3	$330K	Sell	40,431 -218,647	-84%	-$2.19M	﹤0.01%	2357
2024 Q2	$3.39M	Buy	+259,078	New	+$7.73M	0.01%	1212
2024 Q1	–	Sell	-980	Closed	-$66.3K	–	2436
2023 Q4	$66.3K	Buy	980 +393	+67%	+$24.1K	﹤0.01%	2296
2023 Q3	$42.4K	Buy	+587	New	+$46.9K	﹤0.01%	2291
2022 Q4	–	Sell	-15,310	Closed	-$1.91M	–	2216
2022 Q3	$1.91M	Buy	+15,310	New	+$1.82M	﹤0.01%	1222

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

AQR Capital Management's DNA Position: Q2 2026 in Review

AQR Capital Management increased its Ginkgo Bioworks (DNA) stake by 111% in Q2 2026, buying an estimated $2.73M and bringing the position to 621,625 shares worth $6.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

AQR Capital Management first reported a position in DNA in Q3 2022 and has held it in 12 quarters since. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

AQR Capital Management held 621,625 shares of Ginkgo Bioworks worth $6.16M as of Q2 2026.
AQR Capital Management bought 326,837 Ginkgo Bioworks shares in Q2 2026, an estimated $2.73M.
Ginkgo Bioworks made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1871 holding.
AQR Capital Management first reported a position in Ginkgo Bioworks in Q3 2022 and has held it in 12 quarters since.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.